Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
An open label single arm phase II trial in patients with advanced unresectable previously
treated oesophagogastric adenocarcinoma which is MGMT deficient.